| Jun 4 |
The Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR
|
| Jun 4 |
3 Dividend Stocks That Even Ken Griffin Is Buying
|
| Jun 3 |
Hedge Funds are Bullish on This Gene Therapy Stock
|
| Jun 3 |
Gilead, Arcus combo significantly reduces death risk in colorectal cancer
|
| Jun 3 |
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
|
| Jun 3 |
Top Stock Reports for NextEra Energy, BP & Gilead Sciences
|
| Jun 3 |
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
|
| Jun 3 |
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
|
| Jun 2 |
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
|
| Jun 1 |
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
|
